Fulcrum Therapeutics (FULC)

• Market cap: $194M
• 1 day: 5.48%
• 5 days: 6.65%
• 1 month: 33.68%
• 3 months: -7.89%
• 6 months: 18.83%
• Year to date: -20.45%
• 1 year: -46.00%
• 5 years: -69.49%
• 10 years: -71.48%
• Sector: Healthcare
• Industry: Biotechnology

About: Fulcrum Therapeutics Inc is a clinical-stage biopharmaceutical company. The company's programs in clinical development are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy (FSHD) and FTX-6058, a small molecule designed to increase expression of fetal hemoglobin for the treatment of sickle cell disease and other hemoglobinopathies, including beta-thalassemia.

Employees: 45

Fund manager confidence

Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)

2,399% more call options, than puts

Call options by funds: $5.45M | Put options by funds: $218K

24% more capital invested

Capital invested by funds: $196M [Q3] → $243M (+$46.5M) [Q4]

7.72% more ownership

Funds ownership: 88.01% [Q3] → 95.73% (+7.72%) [Q4]

9% less funds holding

Funds holding: 130 [Q3] → 118 (-12) [Q4]

18% less repeat investments, than reductions

Existing positions increased: 33 | Existing positions reduced: 40

27% less first-time investments, than exits

New positions opened: 24 | Existing positions closed: 33

100% less funds holding in top 10

Funds holding in top 10: 2 [Q3] → 0 (-2) [Q4]

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

• Low target: $4 4% upside
• Avg. target: $4 4% upside
• High target: $4 4% upside

1 analyst rating

• positive: 0 0%
• neutral: 1 100%
• negative: 0 0%

HC Wainwright & Co. Andrew Fein 32% 1-year accuracy 113 / 354 met price target

4% upside $4

Neutral Reiterated

26 Feb 2025